Several analysts have recently updated their ratings and price targets for GlaxoSmithKline (LON: GSK):

  • 12/6/2017 – GlaxoSmithKline was given a new GBX 1,450 ($19.52) price target on by analysts at Bank of America Corp. They now have a “neutral” rating on the stock.
  • 12/1/2017 – GlaxoSmithKline had its price target lowered by analysts at Morgan Stanley from GBX 1,450 ($19.52) to GBX 1,400 ($18.84). They now have an “underweight” rating on the stock.
  • 12/1/2017 – GlaxoSmithKline was given a new GBX 1,775 ($23.89) price target on by analysts at Goldman Sachs Group Inc. They now have a “buy” rating on the stock.
  • 11/30/2017 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 11/30/2017 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 1,330 ($17.90) price target on the stock.
  • 11/27/2017 – GlaxoSmithKline was upgraded by analysts at UBS AG to a “buy” rating. They now have a GBX 1,550 ($20.86) price target on the stock.
  • 11/22/2017 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 11/22/2017 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at HSBC Holdings PLC. They now have a GBX 1,925 ($25.91) price target on the stock.
  • 11/16/2017 – GlaxoSmithKline had its price target lowered by analysts at Jefferies Group LLC from GBX 1,540 ($20.73) to GBX 1,450 ($19.52). They now have a “buy” rating on the stock.
  • 11/9/2017 – GlaxoSmithKline had its “sell” rating reaffirmed by analysts at Societe Generale.
  • 11/9/2017 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at Citigroup Inc..
  • 11/9/2017 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,760 ($23.69) price target on the stock.
  • 11/8/2017 – GlaxoSmithKline had its price target lowered by analysts at Beaufort Securities from GBX 1,800 ($24.23) to GBX 1,450 ($19.52). They now have a “buy” rating on the stock.
  • 11/6/2017 – GlaxoSmithKline was downgraded by analysts at Investec to a “hold” rating. They now have a GBX 1,390 ($18.71) price target on the stock, down previously from GBX 1,800 ($24.23).
  • 11/6/2017 – GlaxoSmithKline was given a new GBX 1,450 ($19.52) price target on by analysts at Morgan Stanley. They now have a “sell” rating on the stock.
  • 11/2/2017 – GlaxoSmithKline had its price target lowered by analysts at Berenberg Bank from GBX 1,835 ($24.70) to GBX 1,760 ($23.69). They now have a “buy” rating on the stock.
  • 11/1/2017 – GlaxoSmithKline had its price target lowered by analysts at Kepler Capital Markets from GBX 1,520 ($20.46) to GBX 1,340 ($18.03). They now have a “reduce” rating on the stock.
  • 10/31/2017 – GlaxoSmithKline had its price target lowered by analysts at Jefferies Group LLC from GBX 1,700 ($22.88) to GBX 1,540 ($20.73). They now have a “buy” rating on the stock.
  • 10/29/2017 – GlaxoSmithKline had its price target lowered by analysts at J P Morgan Chase & Co from GBX 1,570 ($21.13) to GBX 1,330 ($17.90). They now have a “neutral” rating on the stock.
  • 10/27/2017 – GlaxoSmithKline had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 1,450 ($19.52) price target on the stock.
  • 10/27/2017 – GlaxoSmithKline was given a new GBX 1,775 ($23.89) price target on by analysts at Goldman Sachs Group Inc. They now have a “buy” rating on the stock.
  • 10/27/2017 – GlaxoSmithKline had its “under review” rating reaffirmed by analysts at Investec.
  • 10/27/2017 – GlaxoSmithKline was given a new GBX 1,610 ($21.67) price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 10/26/2017 – GlaxoSmithKline was given a new GBX 1,550 ($20.86) price target on by analysts at Bank of America Corp. They now have a “neutral” rating on the stock.
  • 10/26/2017 – GlaxoSmithKline was given a new GBX 1,600 ($21.53) price target on by analysts at Morgan Stanley. They now have a “sell” rating on the stock.
  • 10/26/2017 – GlaxoSmithKline was given a new GBX 1,500 ($20.19) price target on by analysts at S&P Global. They now have a “neutral” rating on the stock.
  • 10/26/2017 – GlaxoSmithKline was given a new GBX 1,925 ($25.91) price target on by analysts at . They now have a “buy” rating on the stock.
  • 10/26/2017 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,610 ($21.67) price target on the stock.
  • 10/25/2017 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,760 ($23.69) price target on the stock.
  • 10/23/2017 – GlaxoSmithKline was given a new GBX 1,600 ($21.53) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 10/23/2017 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at Beaufort Securities. They now have a GBX 1,800 ($24.23) price target on the stock.
  • 10/23/2017 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 1,570 ($21.13) price target on the stock.
  • 10/23/2017 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 10/18/2017 – GlaxoSmithKline was given a new GBX 1,600 ($21.53) price target on by analysts at Morgan Stanley. They now have a “sell” rating on the stock.
  • 10/17/2017 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc. They now have a GBX 1,900 ($25.57) price target on the stock.
  • 10/16/2017 – GlaxoSmithKline had its price target raised by analysts at Jefferies Group LLC from GBX 1,675 ($22.54) to GBX 1,700 ($22.88). They now have a “buy” rating on the stock.
  • 10/12/2017 – GlaxoSmithKline was given a new GBX 1,610 ($21.67) price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 10/11/2017 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,610 ($21.67) price target on the stock.
  • 10/10/2017 – GlaxoSmithKline was given a new GBX 1,550 ($20.86) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.

GlaxoSmithKline plc (GSK) traded up GBX 0.56 ($0.01) on Wednesday, reaching GBX 1,279.56 ($17.22). 5,045,931 shares of the company traded hands, compared to its average volume of 11,650,000. GlaxoSmithKline plc has a 52 week low of GBX 1,277.50 ($17.19) and a 52 week high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last released its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%.

The company also recently declared a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be issued a GBX 19 ($0.26) dividend. This represents a yield of 1.41%. The ex-dividend date is Thursday, November 9th.

In other news, insider Simon Dingemans purchased 1,076 shares of the business’s stock in a transaction on Thursday, October 12th. The stock was purchased at an average cost of GBX 1,527 ($20.55) per share, with a total value of £16,430.52 ($22,113.76). Also, insider Urs Rohner purchased 473 shares of the business’s stock in a transaction on Wednesday, October 25th. The stock was purchased at an average cost of GBX 1,518 ($20.43) per share, with a total value of £7,180.14 ($9,663.71). Over the last three months, insiders acquired 1,576 shares of company stock valued at $2,400,376.

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.